SENTI BIOSCIENCES, INC. Senti Biosciences, Inc. announced multiple presentations highlighting the broad application of its Gene Circuit technologies in multiple modalities at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Los Angeles, CA. The presentations and posters can be accessed on the Scientific Presentations & Publications section of the Senti Bio website. High-throughput engineering of Logic Gated-gene circuits for precision CAR cell therapies: Senti Bio has developed a robust platform for automated high throughput screening (HTS) of hundreds of CARs in parallel, in one self-contained, concurrent, end-to-end process.
Automated HTS enables the programming of Logic Gated CAR cells to achieve high protection of healthy cells using the NOT GATE technology without compromising tumor-killing function. The data validates the Company's NOT GATE technology in T cells as well as NK cells, thus enabling the ability to expand the Logic Gate technology into a wide range of cancers. In collaboration with BlueRock Therapeutics: Senti Bio discovered and validated M1-state-specific macrophage promoters that can be rationally re-engineered to improve promoter strength and M1 state-specific activity.
State-specific synthetic promoter libraries were bioinformatically designed for high-throughput Massively Parallel Reporter Assay (MPRA) screening. The data shows that hits from these promoter libraries can be stronger and more selective than native promoters. The data demonstrated that state-specific promoters can be built into Smart Sensor circuits to control macrophage polarization logic.
Engineering a gene circuit-enabled cell therapy with a Tamoxifen regulated safety switch for inducible cell death in human pluripotent stem cells (hPSCs) and their derivatives. BlueRock Therapeutics poster utilizing Senti Bio's Gene Circuit technology: One potential safeguard against risks associated with hPSCs is the implementation of a safety switch that can ablate transplanted cells from a patient. Senti Bio's Safety Switch gene circuit has been successfully engineered into BlueRock's hPSCs for robust, stable, and ubiquitous expression of biological cargo.
BlueRock has demonstrated that hPSCs harboring a novel TamCasp9-engineered Safety Switch gene circuit, expressed robustly from the GAPDH locus, enables transplanted cells to be removed with pharmacologically relevant concentrations of tamoxifen metabolites.
